<DOC>
	<DOCNO>NCT01759030</DOCNO>
	<brief_summary>The purpose study prove efficacy , safety immunogenicity BCD-020 equivalent MabThera use combination methotrexate treatment patient rheumatoid arthritis</brief_summary>
	<brief_title>Study Safety Efficacy BCD-020 Comparing MabThera Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This international multicenter double-blind randomize clinical study efficacy safety ( Phase III ) active comparator ; study provide additional evaluation interchangeability rituximab biosimilar original product MabThera . The study include 308 subject active seropositive rheumatoid arthritis intolerance inadequate response current therapy regimens include one TNF inhibitor , contraindication TNF inhibitor . The first 24-week stage include one course rituximab therapy . The first study stage propose central randomization 2 large group ( 1:1 ) : patient first group recieve BCD-020 ( rituximab manufacture CJSC BIOCAD ) dose 1000 mg drop-wise manner day 1 day 15 ; patient second group recieve MabThera regimen . On final visit Stage 1 ( visit 11 week 24 ) efficacy parameter must evaluate . If disease activity remain ( DAS28 score ≥2.6 increase 0.6 point compare last measurement ) patient recieve another course rituximab treatment . In case partial crossover ( Stage 2 ) take place ( mean second randomization ) : one half patient active RA , previously treat BCD-020 , receive MabThera dose 1000 mg day 1 day 15 ; one half patient active RA , previously treat MabThera , receive BCD-020 dose 1000 mg ion day 1 day 15 . After first rituximab infusion perform retreatment , patient undergo 24-week follow-up ( count start date retreatment initiation ) . Thus , effect switch BCD-020 MabThera vice versa assess 24 week crossover ( Stage 2 study ) . Patients remission RA ( DAS28 &lt; 2.6 ) report week 24 count initial randomization undergo follow next 24 week . During period attend 3 visit ( week 32 , 40 48 ) order monitor disease . If exacerbation occur within time period correspond week 32 week 40 , patient invite study site out-of-schedule visit . If disease exacerbation confirm , he/she undergoes second randomization , second rituximab treatment course follow 6 month ( describe ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Having sign write informed consent form . Patients must 18 80 year age ( age inclusive ) Rheumatoid arthritis confirm accord ACR 1987 criterion . Seropositive rheumatoid arthritis . Active rheumatoid arthritis last 3 month . Disease score accord DAS28 3.2 , TJC≥8 ( 68 ) , SJC≥8 ( 66 ) , hsCRP≥6 mg/l , ESR≥28 mm/hr ( Westergren ) moment screen . Patient 's functional status class IIII accord ACR classification Inadequate response DMARDs include one TNF inhibitor , intolerance contraindication TNF inhibitor . Necessity methotrexate treatment last 4 week prior screen period stable/consistent dosage 7.5 20 mg per week . Patient 's ability ( Investigator 's opinion ) follow protocol procedure ; Willingness use contraception study period . Patients Felty 's syndrome ( irrespectively clinical form ) . Patient 's functional status class IV accord ACR classification . Rheumatoid arthritis low activity ( le 3.2 accord DAS28 ) . Concomitant therapy : Previous treatment biological drug product cause CD20+ lymphocyte depletion , include biological investigational drug . Treatment azathioprine within 28 day study initiation leflunomide within 8 week study 's principal phase ( treatment rituximab ) . Intraarticular glucocorticosteroids within 4 week study 's principal phase ( treatment rituximab ) . Necessity prednisone equivalent administration dose 10 mg per day . Necessity prednisone equivalent administration dose ≤10 mg per day case dose n't stable/consistent last 4 week . Necessity administration nonsteroidal antiinflammatory drug arthritis treatment case dose stable/consistent last 4 week . Pregnancy breastfeed . Changes laboratory value : Hemoglobin level le 100 g/l ; Leucocyte level le 3,0×10e9/l ; Absolute neutrophil count le 1,5×10e9/l ; Thrombocyte level less 100×10e9/l . Confirmed chicken pox within 30 day inclusion screen . Confirmed herpes zoster infection . Acute form infectious disease , history chronic infection severe clinical manifestation . Active tuberculosis , history latent tuberculosis . Inflammatory disease joint ( present anamnesis ) relate rheumatoid arthritis ( include gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease others ) systemic autoimmune disease ( include systemic lupus erythematosus , Crohn 's disease , ulcerative colitis , systemic scleroderma , inflammatory myopathy , mixed form connective tissue inflammatory disease , crosssyndrome others ) . Juvenile idiopathic arthritis juvenile rheumatoid arthritis and/or rheumatoid arthritis develop age 16 . Any determined immunodeficiency . Pernicious anemia . Confirmed cobalamine deficiency . Other somatic disease ( apart rheumatoid arthritis ) increase probability adverse event study influence estimation symptom manifestation RA ; mask , enhance alter symptom RA cause clinical laboratory symptom similar RA ; Positive result serological test Hepatitis B surface antigen ( HbsAg ) presence Hbc IgM together positive result HBV PCR test , presence antibody Hepatitis C virus , syphilis HIV . Major surgery within 28 day prior trial principal phase ( treatment rituximab ) . Any mental disorder , include major depression and/or suicidal thought anamnesis , Investigator 's opinion , create risk patient influence patient 's ability follow study protocol . Unstable angina pectoris . Myocardial infarction within less 1 year prior participation study . Severe central peripheral nervous system disease . Drug addiction , alcoholism . Known hypersensitivity murine proteins component medication use treatment , methotrexate , folic acid drug use premedication . Presence malignant neoplasm , exception adequately treat basal cell carcinoma cervical carcinoma situ malignancy complete remission 5 year ; Simultaneous participation clinical trial , well former participation clinical trial within 3 month study initiation ; previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rheumatoid arthritis , DMARDs</keyword>
	<keyword>rituximab</keyword>
	<keyword>biosimilar</keyword>
	<keyword>interchangeability</keyword>
</DOC>